Across TCGA pan-cancer cohorts, RPS5 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RPS5 data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RPS5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPS5 expression acts as an unfavorable survival marker.
LUAD, SKCM, and PRAD are the cancer types where RPS5 Mutation most reproducibly stratifies survival.